# ANF-Rho in the Treatment of Chronic Neutropenia

> **NCT02533362** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Prolong Pharmaceuticals**

## Conditions studied

- Neutropenia, Severe Chronic

## Interventions

- **DRUG:** ANF-Rho

## Key facts

- **NCT ID:** NCT02533362
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-10
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533362, "ANF-Rho in the Treatment of Chronic Neutropenia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02533362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*